RankAlpha logo
Back to Rankings

ADAG

AdageneA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
Primary-source updates improved the setup: April 2026 data showed 31% confirmed ORR in combined 20 mg/kg cohorts versus 13% at 10 mg/kg, responses in the 20 mg/kg cohorts remained durable, and management now guides cash runway into early 2028 with added collaboration breadth from Incyte/Sanofi/Roche [#PR-2026-04-01] [#PR-2026-04-02-data] [#PR-2026-04-02-incyte].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -2.0.
What can break
April 2026 financing improves runway but adds dilution and can anchor the stock near deal terms.
Momentum
94
Value
41
Sentiment
71
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.10 · Bull $6.25 · Bear $2.40
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $8.67
Why
Momentum94 · Δ7d -2.0
Value41 · Δ7d +0.1
Sentiment71 · Δ7d +5.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
94
34% active weight
Current posture
7d trendFlat
Δ7d
-2.0
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
71
33% active weight
Current posture
7d trendImproving
Δ7d
+5.5
Δ21d
-
Why this grade

Composite grade A. Momentum 94.2 / Value 41.1 / Sentiment 70.9

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$160.64M
Beta
0.72
Shares Out
58.91M
P/E (TTM) · Derived
-4.3
P/S (TTM)
812.92
P/FCF (TTM) · Derived
-4.61
Rev YoY
-87.3%
EPS YoY
+25.7%
Gross Margin
-
Op Margin
-32284.9%
Net Debt
-$66.98M
Current Ratio
2.29
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology